Despite Reductions In NHI Prices Kyowa Hakko Kirin Reports Strong Pharma Sales, Revises Full Year Forecast
This article was originally published in PharmAsia News
Executive Summary
Despite National Health Insurance reimbursement price reductions, major drug maker Kyowa Hakko Kirin still saw a 52 percent increase in pharmaceutical sales and a 71 percent rise in operating income, which the company attributed to the synergy of the newly merged company during a third-quarter earnings call Jan 30